European Gram Negative AntiBacterial Engine


To receive our quarterly newsletter and learn more on ENABLE project and its achievements, 

please send an email to Lilian Löwenau and Clément Robijns at

Your e-mail address will be used solely for the purposes of sending out our newsletter. You will be able to unsubscribe at any time and thereby revoke your consent to receive the newsletter.



ENABLE Video published

November 6, 2018

The video introduces ENABLE, its drug discovery platform, expert network and explains how to submit an Expression of Interest (EoI). You can watch the video on Youtube.

Coordinated Press Release: Tackling Antimicrobial Resistance: ENABLE Selects First Clinical Candidate
October 16, 2018

Apramycin has been selected as clinical candidate for the treatment of critical systemic infections caused by Gram-negative bacteria. You can download the Juvabis Press Release in the section below.

ENABLE at the 11th Berlin Conference on Life Sciences
February 28, 2018

The Berlin Conference on “Novel Antimicrobials and AMR Diagnostics” took place on March 2nd, 2018 in the Fraunhofer-Forum in Berlin. The conference brought together more than 200 people from science and business, investors and policy makers, startups and health economists to highlight the most promising technologies, to showcase best-practice examples and discuss successful business strategies in the AMR market. Together with the European Investment Bank, CARB-X and GARDP, ENABLE contributed to the program and took part in the interactive market place – a session on financing and funding opportunities for SMEs active in the AMR field.


Press Release published

December 19, 2017

Please find the ENABLE Press Release in the section below.

ENABLE in Nordic Life Science Magazine

November 4, 2017
Report about ENABLE in the Nordic Life Science Magazine

Health Check Survey

October 9, 2017

ENABLE partners were asked in a Health Check Survey how satisfied they are within the ENABLE project. In a slide deck (please scroll to the bottom of this page for download) ,we have summed up the feedback and suggested improvements.

New IMI Video #CarryTheTorch

June 30, 2017

"Infections we treated for decades can once again kill". IMI launched a new video on medical research today: #CarryTheTorch connects the scientific giants of the past to the important work being carried out today. Watch the movie on youtube:

 ENABLE releases its third external newsletter

May 22, 2017 

We are pleased to present our four new partners and give an update on the reviews that took place within the consortium. Please find this new issue below. To suscribe and receive them directly, please send us an email via


April 24, 2017

Meet us at the poster presentation corner and get to know the ENABLE project! You can also have a look at the poster we are presenting here

Open Call for expertise and capabilities in non-clinical development

February 15, 2017

Thanks to all applicants! We will come back to you shortly.

ENABLE goes live on Twitter

January 27, 2017

To stay updated about the project and related fields, follow us on Twitter.

To contribute and help us become a trend, use #ENABLE 

 Have a look at our Twitter account 

 ENABLE released its second external newsletter

January 24th, 2017

This new issue presents ENABLE achievements during Q4 2016. We also took the opportunity to present our partner Nosopharm and a joint initiative from the ND4BB program: DRIVE-AB. Please find the second issue of our Newsletter in the section below. To suscribe to our newsletter and receive them directly, please contact Dr Nathalia Murillo:


ENABLE consortium co-organized the Frontiers in Antibiotic Drug Discovery (FiADD) in Stockholm

September 12-13, 2016

Together with the Swedish Pharmaceutical Society, ENABLE co-organized a two-day conference to showcase future opportunities for antibacterial drug research.

Please about this conference in our 2nd Newsletter, in the section below. 

To suscribe to our newsletter and receive them directly, please contact Dr Nathalia Murillo:

ENABLE held its third Annual Meeting in Stockholm

September 12-13, 2016

77 representatives from ENABLE partners gathered in the Royal Coin Cabinett to listen to the latest advances of ENABLE programmes.

Please find full report by clicking here

ENABLE held a workshop on antimicrobial resistance during the BIO Convention 

June 6, 2016

We were pleased to welcome more than 100 delegates during this workshop. Ten companies presented their novel antibiotics and AMR innovation. Congratulations to Bioversys and Episiome who respectively won the Expert Pannel Best Presentation Award and the Audience Best Presentation Award!

Please find full report and slide by clicking here.


ENABLE introduces a rolling deadline for expressions of interest submitted to the project

October 1st, 2015 

From October 1 2015, potential programmes for inclusion in ENABLE can submit an expression of interest (EoI) at any time for assessment and development for full review by the ENABLE Portfolio Management Committee. For full details about the Open Call Process, please visit the Join Us ! page

ENABLE holds its first annual meeting in Copenhagen

May 26-27, 2015

Bringing together 80 members of the project from 32 partners, the 3-day meeting heard from all the active programmes in ENABLE together with programme development meetings, expert external speakers and alignment of the project within the wider ND4BB family of projects.

The Research Network joins the ENABLE programme 

March 2015

We are pleased to welcome this UK-based research center into our consortium. It brings to our portfolio a novel gram negative programme, developed through previous international academic research. 


ENABLE is officially launched !
April 10th 2014
Our managing entity, University of Uppsala, welcomed the whole consortium for two days in order to officially launch the ENABLE initiative.


ENABLE joins the AMR Challenge

January 2019

The AMR Challenge is a way for governments, private industries, and non-governmental organizations worldwide to make formal commitments that further the progress against antimicrobial resistance. ENABLE's commitment has been published here.

ENABLE at the 12th Berlin Conference on Life Sciences

14 - 15 March, 2019

The Novel Antimicrobials and AMR Diagnostics 2019 conference is a platform for SMEs, start-ups, big pharma, academia, investors and public institutions to discuss strategies and the specific challenges faced by SMEs in bringing new antimicrobial treatments and diagnostics to the market. ENABLE representatives will join to the conference as speakers.

Information about ENABLE no-cost extension

ENABLE is at an advanced stage in seeking approval from IMI for a 1 year no-cost extension. The request is for an extension in time (End Date 31/01/2021) and also in scope. The broadening of ENABLE scope will allow us to consider programmes with direct acting antibacterial compounds targeting the Enterobacteriaceae, P. aeruginosa, and/or A. baumannii, and to consider programmes submitted by any individual EFPIA member (not only those currently in ENABLE).

Expressions of Interest may be submitted to ENABLE by academic groups, SMEs, or individual EFPIA members up until 26. August 2019. At this stage we do not know for certain whether a 1 year no cost extension will be approved but the initial informal feedback from IMI has been positive. Although formalization through an amendment will take some time, IMI has given the green light to plan for the extension. We therefore encourage any eligible groups or organizations to begin preparing their submission to ENABLE for no later than 26. August 2019.

6th ENABLE Annual Meeting held in Warsaw

24 - 25 September 2019

From 24-25 September 2019, this year’s ENABLE Annual Meeting took place in Warsaw, Poland. The meeting achieved an all-time high attendance record with over 90 attendees. The public-private partnership initiative with partners from EFPIA companies, SMEs, academia and independent experts met to discuss the progress of the quickly developing programmes. As ENABLE is coming to an end in 2021 including the one-year extension, the meeting presented the last opportunity for new teams to enter the initiative.

 At this time, the ENABLE project has received 110 Expressions of Interest. Around half of these applications were able to present in front of the expert body of ENABLE, the Portfolio Management Committee. Again, around half of the Expressions of Interest were approved and received funding from ENABLE resources. Currently, the engine progresses eight programmes.

Article on ENABLE published: Scientists aim for new weapons in fight against superbugs

14 October 2019

"New weapons are needed to fight drug-resistant bacteria, one of the biggest threats to global health. By working on new antibiotics or finding ways to revive existing ones in our medical arsenal, scientists aim to avoid a return to a world where even everyday infections may mean death." Anders Karlén and Diarmaid Hughes gave an interview to the HORIZON EU Research & Innovation Magazine. You can read the article here.

Two ENABLE Press Releases published

18 November 2019

A Press Release on the candidate selection of Mutabilis and the entry into Phase I by Juvabis. Both press releases can be downloaded here.


ENABLE: Goals achieved - Mission continues

January 2020

The press release can be downloaded here.

Juvabis Announces Positive Phase 1 Results

November 2020

The press release can be downloaded here.


Mutabilis' EBL-1463 programme: A successful case study from ENABLE 

May 2021

The press release can be downloaded here.

Health Check Survey

With any queries regarding the ENABLE project, please contact the Dissemination Manager: 

Clément Robijns
Tel: 0049 (0)30-264 921-58

The research leading to these results has received support from the Innovative Medicine Initiative Joint Undertaking under grant agreement no 115583, resources of which are composed of financial contributions from the European Union`s Seventh Framework Programme (FP7/2007-2013) and EFPIA companies` in kind contribution.